Your browser doesn't support javascript.
COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea.
Baek, Moon Seong; Lee, Min-Taek; Kim, Won-Young; Choi, Jae Chol; Jung, Sun-Young.
  • Baek MS; Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
  • Lee MT; College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
  • Kim WY; Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea.
  • Choi JC; Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
  • Jung SY; Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
PLoS One ; 16(10): e0257641, 2021.
Article in English | MEDLINE | ID: covidwho-1448573
ABSTRACT

BACKGROUND:

Given the rapid increased in confirmed coronavirus disease 2019 (COVID-19) and related mortality, it is important to identify vulnerable patients. Immunocompromised status is considered a risk factor for developing severe COVID-19. We aimed to determine whether immunocompromised patients with COVID-19 have an increased risk of mortality.

METHOD:

The groups' baseline characteristics were balanced using a propensity score-based inverse probability of treatment weighting approach. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated for the risks of in-hospital mortality and other outcomes according to immunocompromised status using a multivariable logistic regression model. We identified immunocompromised status based on a diagnosis of malignancy or HIV/AIDS, having undergone organ transplantation within 3 years, prescriptions for corticosteroids or oral immunosuppressants for ≥30 days, and at least one prescription for non-oral immunosuppressants during the last year.

RESULTS:

The 6,435 COVID-19 patients (≥18 years) included 871 immunocompromised (13.5%) and 5,564 non-immunocompromised (86.5%). Immunocompromised COVID-19 patients were older (60.1±16.4 years vs. 47.1±18.7 years, absolute standardized mean difference 0.738). The immunocompromised group had more comorbidities, a higher Charlson comorbidity index, and a higher in-hospital mortality rate (9.6% vs. 2.3%; p < .001). The immunocompromised group still had a significantly higher in-hospital mortality rate after inverse probability of treatment weighting (6.4% vs. 2.0%, p < .001). Multivariable analysis adjusted for baseline imbalances revealed that immunocompromised status was independently associated with a higher risk of mortality among COVID-19 patients (adjusted odds ratio [aOR] 2.09, 95% CI 1.62-2.68, p < .001).

CONCLUSIONS:

Immunocompromised status among COVID-19 patients was associated with a significantly increased risk of mortality.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunocompromised Host / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunocompromised Host / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article